Baseline characteristics
| Baseline characteristics . | EB (total 532) N (%) . | CNB (total 529) N (%) . | Total 1061 N (%) . | P value . |
|---|---|---|---|---|
| Age (median, IQR) | 63 (18-93) | 64 (19-92) | 63 (18-93) | NS |
| Sex | NS | |||
| Male | 315 (59.2) | 295 (55.8) | 610 (57) | |
| Female | 217 (40.8) | 234 (44.2) | 451 (43) | |
| Stage | <.0001 | |||
| I-II | 252 (47) | 185 (35) | 437 (41) | |
| III-IV | 280 (53) | 352 (65) | 632 (59) | |
| IPI | <.0001 | |||
| 0-2 | 387 (73) | 317 (60) | 704 (66) | |
| 3-5 | 145 (27) | 212 (40) | 357 (34) | |
| Performance status | NS | |||
| <2 | 484 (91) | 464 (88) | 948 (89) | |
| ≥2 | 46 (9) | 64 (12) | 110 (11) | |
| Histology at diagnosis | NS | |||
| DLBCL | 514 (97) | 504 (95) | 1018 (96) | |
| PMBL | 18 (3) | 25 (5) | 43 (4) | |
| Elevated LDH | 206 (39) | 304 (58) | 510 (48) | <.0001 |
| No of EN sites | NS | |||
| ≤1 | 427 (80) | 420 (79) | 847 (80) | |
| >1 | 105 (20) | 109 (21) | 214 (20) | |
| DTI in days (median, IQR) | 19 (0-98) | 14 (0-69) | 15 (0-98) | <.0001 |
| Frontline treatment | NS | |||
| RCHOP/MRCHOP | 408 (77) | 378 (71) | 786 (74) | |
| Other RCHOP-based regimen∗ | 59 (11) | 58 (11) | 117 (11) | |
| Other IC† | 20 (4) | 34 (6) | 54 (5) | |
| Non-IC‡ | 39 (7) | 48 (9) | 87 (8) | |
| Missing | 6 (1) | 11 (2) | 17 (2) | |
| Adequacy of tissue | <.000001 | |||
| Inadequate | 78 | 151 | 223 | |
| Adequate | 371 | 271 | 624 | |
| No available | 83 | 107 | 205 |
| Baseline characteristics . | EB (total 532) N (%) . | CNB (total 529) N (%) . | Total 1061 N (%) . | P value . |
|---|---|---|---|---|
| Age (median, IQR) | 63 (18-93) | 64 (19-92) | 63 (18-93) | NS |
| Sex | NS | |||
| Male | 315 (59.2) | 295 (55.8) | 610 (57) | |
| Female | 217 (40.8) | 234 (44.2) | 451 (43) | |
| Stage | <.0001 | |||
| I-II | 252 (47) | 185 (35) | 437 (41) | |
| III-IV | 280 (53) | 352 (65) | 632 (59) | |
| IPI | <.0001 | |||
| 0-2 | 387 (73) | 317 (60) | 704 (66) | |
| 3-5 | 145 (27) | 212 (40) | 357 (34) | |
| Performance status | NS | |||
| <2 | 484 (91) | 464 (88) | 948 (89) | |
| ≥2 | 46 (9) | 64 (12) | 110 (11) | |
| Histology at diagnosis | NS | |||
| DLBCL | 514 (97) | 504 (95) | 1018 (96) | |
| PMBL | 18 (3) | 25 (5) | 43 (4) | |
| Elevated LDH | 206 (39) | 304 (58) | 510 (48) | <.0001 |
| No of EN sites | NS | |||
| ≤1 | 427 (80) | 420 (79) | 847 (80) | |
| >1 | 105 (20) | 109 (21) | 214 (20) | |
| DTI in days (median, IQR) | 19 (0-98) | 14 (0-69) | 15 (0-98) | <.0001 |
| Frontline treatment | NS | |||
| RCHOP/MRCHOP | 408 (77) | 378 (71) | 786 (74) | |
| Other RCHOP-based regimen∗ | 59 (11) | 58 (11) | 117 (11) | |
| Other IC† | 20 (4) | 34 (6) | 54 (5) | |
| Non-IC‡ | 39 (7) | 48 (9) | 87 (8) | |
| Missing | 6 (1) | 11 (2) | 17 (2) | |
| Adequacy of tissue | <.000001 | |||
| Inadequate | 78 | 151 | 223 | |
| Adequate | 371 | 271 | 624 | |
| No available | 83 | 107 | 205 |
EN, extranodal sites; IC, immunochemotherapy; IQR, interquartile range; LDH, lactate dehydrogenase; MRCHOP, methotrexate with cyclophosphamide, doxorubicin, vincristine, prednisone; N, number of patients; NS, not significant; %, percentage.
Other RCHOP-based regimens include RCHOP + lenalidomide, RCHOP + everolimus, RCHOP + ibritumomab tiuxetan.
Other IC other nonanthracycline based immunochemotherapies.
Non-IC include rituximab and steroids based regimens without chemotherapy.